株式会社エヌビィー健康研究所
事業所案内
オリジナルシーズ開発 ナレッジプロセスアウトソーシングサービス 創薬研究ツール提供 技術文献・総説

技術文献・総説

  • Ogawa M, Suzuki J, Takayama K, Isobe M. (2009) Matrix metalloproteinase suppression induced by clarithromycin in murine cardiac allografts.Transplant Proc. 41(1):395-7.

  • Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, Yoneda Y,　Shapiro SD, Takayama K. (2009) Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med. 179(4):271-8.

  • Hishikari K, Suzuki J, Ogawa M, Isobe K, Takahashi T, Onishi M, Takayama K, Isobe M. (2009) Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res. 81(1):123-32.

  • Wakatsuki S, Suzuki J, Ogawa M, Masumura M, Muto S, Shimizu T, Takayama K, Itai A, Isobe M. (2008 ) A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration. Expert Opin Ther Targets. 12(12):1469-76.

  • Takayama K, Sukhova GK, Chin MT, Libby P．(2006). A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res. 98(4):499-504

  • Feinberg, M. W., Shimizu, K., Lebedeva, M., Haspel, R., Takayama, K., Chen, Z., Frederick, J. P., Wang, X. F., Simon, D. I., Libby, P., et al. (2004). Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res 94, 601-608.

  • Shimizu, K., Aikawa, M., Takayama, K., Libby, P., and Mitchell, R. N. (2003). Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108, 2113-2120.

  • Takayama, K., Garcia-Cardena, G., Sukhova, G. K., Comander, J., Gimbrone, M. A., Jr., and Libby, P. (2002). Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277, 44147-44154.

  • Tanaka, Y., Takahashi, A., Watanabe, K., Takayama, K., Yahata, T., Habu, S., and Nishimura, T. (1996). A pivotal role of IL-12 in Th1-dependent mouse liver injury. Int Immunol 8, 569-576.

  • Shikano, M., Masuzawa, Y., Yazawa, K., Takayama, K., Kudo, I., and Inoue, K. (1994). Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A2 during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanolamine. Biochim Biophys Acta 1212, 211-216.

  • Fujimori, Y., Murakami, M., Kim, D. K., Hara, S., Takayama, K., Kudo, I., and Inoue, K. (1992). Immunochemical detection of arachidonoyl-preferential phospholipase A2. J Biochem (Tokyo) 111, 54-60.

  • Takayama, K., Kudo, I., Kim, D. K., Nagata, K., Nozawa, Y., and Inoue, K. (1991). Purification and characterization of human platelet phospholipase A2 which preferentially hydrolyzes an arachidonoyl residue. FEBS Lett 282, 326-330.

  • Takayama, K., Hara, S., Kudo, I., and Inoue, K. (1991). Detection of 14-kDa group II phospholipase A2 in human seminal plasma. Biochem Biophys Res Commun 178, 1505-1511.

  • Murakami, M., Takayama, K., Umeda, M., Kudo, I., and Inoue, K. (1991). Preparation of antibodies to phospholipases A2. Methods Enzymol 197, 223-233.

  • Baek, S. H., Takayama, K., Kudo, I., Inoue, K., Lee, H. W., Do, J. Y., and Chang, H. W. (1991). Detection and characterization of extracellular phospholipase A2 in pleural effusion of patients with tuberculosis. Life Sci 49, 1095-1102.

  • Takayama, K., Kudo, I., Hara, S., Murakami, M., Matsuta, K., Miyamoto, T., and Inoue, K. (1990). Monoclonal antibodies against human synovial phospholipase A2. Biochem Biophys Res Commun 167, 1309-1315.

  • 高山喜好　工藤一郎　井上圭三　細胞質ホスホリパーゼＡ２活性測定法 実験医学　Vol.11 No.3　(増刊) 1992 307-310

  • 高山喜好　工藤一郎　ホスホリパーゼと炎症 炎症と免疫　Vol.３ No.1 1995 7-13

  • 田中善孝，高橋晶子，高山喜好，渡辺一仁，西村孝司　肝障害におけるIL-12の役割 炎症と免疫　Vol.5 No.3 1997 244-251

  • 高山喜好　マクロファージに発現する抗炎症作用レセプター，EP4とその治療への応用　医学のあゆみ　Vol.209　No.8　2004/5/22 465-469

  • 高山喜好　慢性閉塞性肺疾患治療薬の基礎　日本薬理学雑誌, 127(4) 304-307, 2006

  • 高山喜好　ゲノム創薬の現状と今後　日本薬理学雑誌, 129(1)　47-50,2007

  • 高山喜好 Lab on a chip技術の創薬研究への応用,　131（1）28−31,　2008
Copyright 2007 NBHL Co. Ltd